Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
CARLSBAD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced its financial results for the quarter ended June 30, 2009. During 2009 Isis has continued to successfully execute its business strategy and
as a result reported $669...
Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
- Program Focuses on Expanding Pipeline of Drugs For People with Type 1 Diabetes -
NEW YORK, Aug. 5 /PRNewswire-USNewswire/ -- The Juvenile Diabetes Research Foundation said today that it has entered into a novel collaborative research agreement with the Genomics Institute of th...
Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
LAUSANNE, Switzerland and
WOBURN, Massachusetts, August 4 /PRNewswire/ --
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group
of companies with a focus on the development of prescription drugs that
target unmet medical needs, and
Mercury Therapeutics, Inc. (Mercury), a
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
TITUSVILLE, N.J., Aug. 3 /PRNewswire/ -- The U.S. Food and
Drug Administration approved INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) extended-release injectable suspension for the acute and
maintenance treatment of schizophrenia in adults on Friday, July 31, 2009. It is the first ...
Medigus and Tower Semiconductor Announce World's Smallest Medical Video Camera Based on Advanced CMOS Image Sensor
MIGDAL HA'EMEK, Israel, August 3 /PRNewswire-FirstCall/ --
Medigus Ltd. (TASE: MDGS) a leading developer of endoscopic and
medical devices, and
Tower Semiconductor, Ltd. (Nasdaq: TSEM , TASE: TASE:
TSEM), a leading global specialty foundry, today announced successful
Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
LEXINGTON, Massachusetts, August 3 /PRNewswire-FirstCall/ -- Shire plc
(LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company,
today reported positive results from the first of three Phase III studies of
velaglucerase alfa, its enzyme replacement therapy in development fo...
John Legend and Gap Join (PRODUCT)RED(TM) to Help Eliminate AIDS in Africa with Exclusive (RED)ZONE Seating at Madison Square Garden
NEW YORK, July 29 /PRNewswire/ -- Grammy-Award winning artist and
long-time (PRODUCT)RED supporter John Legend is joining with Gap to create an exclusive (RED)ZONE seating section for his August 13th, 2009 concert at Madison Square Garden in New York City. Beginning July 29th, every purcha...
FDA Advisory Committee Votes in Favor of SAPHRIS(R) (asenapine) for Acute Bipolar I Disorder and Acute Schizophrenia
KENILWORTH, N.J., July 30 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that the U.S. Food and
Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted unanimously in favor of SAPHRIS(R) (asenapine) sublingual tablets a...
Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty-Plus Year Historic Relationship
New agreement outlines an increased level of commitment to clinical care, research and
NEW YORK, July 30 /PRNewswire-USNewswire/ -- Montefiore Medical Center and
Albert Einstein College of Medicine of Yeshiva University today announced a new ten-year agreement to continue t...
Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy
NEWPORT BEACH, Calif., July 28 /PRNewswire/ -- Hoag Memorial Hospital Presbyterian today announced promising data from a clinical study showing patient-specific cancer vaccines derived from patients' own cancer cells and
immune cells were well tolerated and
resulted in impressive lo...
FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents
PHILADELPHIA, July 28 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP,
NASDAQ: SHPGY ), the global specialty biopharmaceutical company, announces
that it has received a Complete Response letter today for INTUNIV(TM)
(guanfacine) Extended Release from the Food and
Drug Administration (FDA).
Cryo-Cell Announces C'elle(SM) Research and Development Collaboration with Cryopraxis Cryobiology Ltd.
Oldsmar, Fla., July 27 /PRNewswire-FirstCall/ --Cryo-Cell International, Inc. (OTC Bulletin Board: CCEL), one of the largest and
most established leaders in stem cell innovation today announced a research and
development collaboration agreement with Cryopraxis Cryobio...
Correction to Earlier Release From Jewish Hospital and University of Louisville
LOUISVILLE, Ky., July 24 /PRNewswire-USNewswire/ -- In today's announcement regarding the use of stem cells in the treatment of heart failure, we failed to make a critical distinction. Louisville researchers and
physicians have performed the world's first phase-one FDA-approved clin...
Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
LACHEN, Switzerland and
HOBOKEN, N.J., July 23 /PRNewswire/ -- Octapharma USA is now accepting applications for the Octapharma 25th Anniversary Grants Program , which supports clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immunot...
Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
DEERFIELD, Ill., July 22, and
OSAKA, Japan, July 23 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, received notification from the U.S. Food and
Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs
INDIANAPOLIS, July 22 /PRNewswire-FirstCall/ -- Eli Lilly and
Company (NYSE: LLY ) announced today during a lease signing event that it has become the first tenant of New York City's new Alexandria Center for Science and
Technology at East River Science Park, a development that sh...
July 2009 Mayo Clinic Women's HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals
Food Storage Safety: Tips to Avoid Food Poisoning
ROCHESTER, Minn., July 22 /PRNewswire-USNewswire/ -- Here are highlights from the July issue of Mayo Clinic Women's HealthSource . You may cite this publication as often as you wish. Mayo Clinic Women's HealthSource ...
July 2009 Mayo Clinic Health Letter Highlights a Positive Outlook, Bell's Palsy and Heart Valve Repair
Studies Show a Sunny Outlook is Good for Health, Longer Life
ROCHESTER, Minn., July 22 /PRNewswire-USNewswire/ -- Here are highlights from the July issue of Mayo Clinic Health Letter. You may cite this publication as often as you wish. Reprinting is allowed for a fee. Mayo...
Teeth and Gums Also Benefit from the Healing Power of Aloe Vera
CHICAGO, July 20 /PRNewswire-USNewswire/ -- The aloe vera plant has a long history of healing power. Its ability to heal burns and
soothe pain has been documented as far back as the 10th century. Recently, aloe vera has gained some popularity as an active ingredient in toot...
New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed
CAPE TOWN, South Africa , July 20 /PRNewswire/ -- New data became available today at the 5(th) International AIDS Society Conference from ARTEN ( A tazanavir/ R itonavir on a background of T enofovir and
E mtricitabine [Truvada(R)] versus N evirapine). ARTEN is an open-label, multi-c...
Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
AIEA, Hawaii, July 20 /PRNewswire/ -- The Centers for Disease Control and
Prevention reported this week that the prevalence of obesity among Americans is now over 26%. Obesity exacerbates a constellation of diseases including diabetes, liver disease, and
heart disease, often in...
International Journal of Occupational and Environmental Health Features Discovery of Asbestos-Related Pain Origin from Scientists at the Karmanos Cancer Institute in Detroit
DETROIT, July 20 /PRNewswire-USNewswire/ -- Scientists at the Barbara Ann Karmanos Cancer Institute's National Center for Vermiculite and
Asbestos-Related Cancers (NCVAC) have discovered a probable reason for the unrelenting chest pain experienced in certain patients with asbestos-r...
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
ROCKVILLE, Maryland and
LONDON, July 20 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) and
GlaxoSmithKline PLC (GSK) today announced that BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) met the primary endpoint in BLISS-52, the first of two pivotal P...
Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
SAN DIEGO, July 17 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity, plans to announce the results of the three remaining Phase 3 clinical trials in the Contrave program on Monday, July 20, 2009 be...
Bionovo's Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
EMERYVILLE, Calif., July 17 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) announced today that a study of the gene regulation in multiple cell lines by several of their estrogen receptor beta (ERb) candidates will be published in Public Library of Science One.
Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
CORK, Ireland, July 16 /PRNewswire/ --Tibotec Pharmaceuticals today announced that it has entered into a license and
collaboration agreement with Gilead Sciences, Inc. for the development and
commercialization of a new once-daily fixed-dose antiretroviral product containing Tibotec's inv...
Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
CALGARY, July 16 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) ('Oncolytics') reported today that Dr. Shizuko Sei et al. published the results of their work examining reovirus and
chemotherapy against human non-small cell lung cancer (NSCLC). The paper, entitled "Syn...
Velos, Inc. Releases Software to Support Cancer Centers With New Workflow and Content for NCI Clinical Trials Reporting Program
FREMONT, Calif., July 16 /PRNewswire/ -- Velos, Inc., the trusted leader in clinical research management systems, announced today the availability of new system capabilities to ensure that the cancer center community can fulfill new registration requirements for the U.S. National Cancer ...
Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference
VIENNA, July 15 /PRNewswire-USNewswire/ -- This week, more than 3,000 leading scientists convened to report and
discuss the latest advances in research on treatments, risk factors, diagnosis and
causes for the health epidemic of the 21st century -- Alzheimer's disease -- at the Alzheimer's As...
Music & Medicine: Unique Collaboration Combines Performing Arts and Science
FORT WORTH, Texas, July 14 /PRNewswire-USNewswire/ -- When Eri Yoshimura begins to play, beautiful music fills the air. Her eyes close, and
her body sways in time to the prelude. Her small hands glide over the keyboard gracefully, fluidly, as if they were tiny ballerinas on a miniature s...
deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke
REYKJAVIK, Iceland, July 13 /PRNewswire-FirstCall/ -- Scientists at
deCODE genetics (Nasdaq: DCGN ) and
colleagues from Europe and
States today report the discovery of a common single-letter variant in the
sequence of the human genome (SNP) conferring increased risk of atrial
GNC Unveils Study Results for First and Only Nitric Oxide Product Clinically Proven to Improve Physical Performance at NSCA Conference in Las Vegas
LAS VEGAS, July 13 /PRNewswire-FirstCall/ -- GNC, the leading global specialty retailer of nutritional products, announced today clinical results for the first and
only nitric oxide product, Amplified Maxertion N.O., proven to demonstrate a delay in the onset of neuromuscular fatigue. The key fin...
Results From Trials of DHA in Alzheimer's Disease and Age-Related Cognitive Decline
VIENNA, Austria, July 12 /PRNewswire/ -- Results from two large studies using DHA, an omega 3 fatty acid, were reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna.
Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
BELLEVILLE, Ontario and
CHADDS FORD, Pa., July 10 /PRNewswire-FirstCall/ -- Bioniche Life Sciences Inc. (TSX: BNC) and
Endo Pharmaceuticals (Nasdaq: ENDP ) jointly announced today that Endo has licensed from Bioniche the exclusive rights to develop and
market Urocidin(TM) in the U.S. with ...
Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial
SEATTLE, July 9 /PRNewswire/ -- Dharma Therapeutics, Inc., ("Dharma") Seattle, WA (a subsidiary of the Transcu Group Limited, a company listed on the Singapore Exchange Limited) announced that its improved active transdermal delivery technology, which administers lidocaine and
epinephrine through ...
Dry Mouth Linked to Prescription and Over the Counter Drugs
BALTIMORE, July 9 /PRNewswire-USNewswire/ -- Approximately ninety-one percent of dentists say patients complaining about dry mouth are taking multiple medications, according to a nationwide member survey conducted by the Academy of General Dentistry (AGD). Dry mouth, or xerostomia , is caused by...
Mayo Clinic Proceedings: A Comprehensive Review of Addiction to Prescription Painkillers Among Patients and Physicians
ROCHESTER, Minn., July 7 /PRNewswire-USNewswire/ -- Chemical dependency and
recovery in patients and
physicians are closely examined in a series of articles and
editorials in the July 2009 issue of Mayo Clinic Proceedings . The subject is especially timely. As the immense challenges, inclu...
Why Do African-Americans Fare Worse With Cancer? Access and Economics Are Only Part of the Story
ANN ARBOR, Mich., July 7 /PRNewswire-USNewswire/ -- An analysis of almost 20,000 patient records from the Southwest Oncology Group's database of clinical trials finds, for the first time, that African-American breast, ovarian, and
prostate cancer patients tend to die earlier than patients of oth...
June 2009 Mayo Clinic Women's HealthSource Highlights Summer Skin Problems, Low Vision and Pilates
ROCHESTER, Minn., July 7 /PRNewswire-USNewswire/ -- Here are highlights from the June issue of Mayo Clinic Women's HealthSource . You may cite this publication as often as you wish. Mayo Clinic Women's HealthSource attribution is required. Reprinting is allowed for a fee. Include the follow...
Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
DALLAS, July 7 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today new preclinical data demonstrating that thiarabine shows remarkable efficacy in the prevention and
treatment of rheumatoid arthritis (RA). In a well-established animal model...